Birth length of at least 50 cm may bump up breast ca risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

An increase in birth length by 2 cm is associated with a 9% increase in breast cancer risk, according to a study reported in PLoS Medicine, online. Isabel dos Santos Silva, MD, PhD, a professor of epidemiology at the London School of Hygiene and Tropical Medicine and colleagues, examined 32 studies involving 22,058 breast cancer cases.

An increase in birth length by 2 cm is associated with a 9% increase in breast cancer risk, according to a study reported in PLoS Medicine, online. Isabel dos Santos Silva, MD, PhD, a professor of epidemiology at the London School of Hygiene and Tropical Medicine and colleagues, examined 32 studies involving 22,058 breast cancer cases.

The researchers found the strongest link between breast cancer and birth size occurred between a length at birth of greater than or equal to 50 cm. In addition to length, a 0.5 kg increment in birth weight, greater than or equal to 3.5 kg, was associated with an estimated 7% increase in the risk of breast cancer (PLoS Med 5: e193, 2008).

“Assuming causality, we estimated that about 5% of all breast cancers in developed countries could be attributable to high birth size,” the researchers wrote. They also said the association between birth size and breast cancer appeared to be largely independent of known risk factors.

“Further research is needed to unravel the biological mechanisms underlying the birth size-breast cancer association,” wrote Dr. Silva’s group.

In an accompanying editorial, Pagona Lagiou, MD, PhD, and Dimitrios Trichopoulos, MD, PhD, both from the epidemiology department at the Harvard School of Public Health in Boston, said while the relative size of the eff ects is small, the individual studies driving the conclusion were of sound epidemiological design. The research relied on objectively documented birth size parameters, allowing little room for bias (PLoS Med 5: e194, 2008).

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.